Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes

Endocrine Journal

Yoshifumi Saisho²  Hiroshi Itoh²  Masami Tanaka²  Toshikatsu Shigihara⁶  Junichiro Irie²  Jiro Morimoto⁷  Shu Meguro²  Ken Yajima¹  Kumiko Tanaka²  Izumi Takei⁵  Toshihide Kawai²  Yoshihito Atsumi⁴  Takatoshi Imai³ 

[1] Department of Internal Medicine, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo, Japan;Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;Department of Internal Medicine, Yokohama Municipal Citizens�? Hospital, Kanagawa, Japan;Diabetes Center, Eiju General Hospital, Tokyo, Japan;Department of Internal Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan;Department of Internal Medicine, Eiju General Hospital, Tokyo, Japan;Department of Internal Medicine, Japan Community Health Care Organization Saitama Medical Center, Saitama, Japan

关键词: Liraglutide;    Metformin;    Type 2 diabetes;    Japanese;    Randomized controlled trial;   

DOI  :  10.1507/endocrj.EJ14-0602

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(41)Cited-By(5)There is little information on direct comparison between metformin and glucagon-like peptide-1 (GLP-1) receptor agonists in the Asian population. This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM). The study was a 24-week, open-labeled, randomized controlled study. Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy. The primary endpoint was change in HbA1c at week 24. Secondary endpoints included changes in daily glycemic profile, body weight, incidence of hypoglycemia and other adverse events. The study, which was originally planned to enroll 50 subjects in each group, was ended with insufficient recruitment. A total of 46 subjects completed the study, and analysis was conducted in this cohort. Reduction in HbA1c at week 24 was comparable between the metformin (n = 24) and liraglutide (n = 22) groups (-0.95 ± 0.80% vs. -0.80 ± 0.88%, p = 0.77), while the liraglutide group reached maximal reduction more rapidly than did the metformin group. There was no significant difference in weight gain or incidence of hypoglycemia between the groups. Diarrhea was more frequent in the metformin group, while constipation was more frequent in the liraglutide group. There was no significant difference in treatment satisfaction between the groups. In conclusion, liraglutide and metformin monotherapy showed similar reduction in HbA1c during 24 weeks, with no difference in weight gain or incidence of hypoglycemia in overweight or obese Japanese patients with T2DM.

【 授权许可】

Unknown